share_log

Sera Prognostics | 10-Q: Q2 2024 Earnings Report

Sera Prognostics | 10-Q: Q2 2024 Earnings Report

Sera Prognostics | 10-Q：2024财年二季报
美股SEC公告 ·  2024/08/08 04:22

Moomoo AI 已提取核心信息

Sera Prognostics reported Q2 2024 financial results with revenue of $24,000 and a net loss of $8.3 million, compared to $123,000 revenue and $10.5 million net loss in Q2 2023. Operating expenses decreased to $9.3 million from $11.6 million year-over-year, driven by reduced selling and marketing costs of $1.8 million and general administrative expenses of $1.2 million.The company maintained a strong financial position with $80.9 million in cash, cash equivalents and marketable securities as of June 30, 2024. Research and development expenses increased by $0.7 million to $4.4 million, primarily due to increased product development activities. The company believes its existing financial resources are sufficient to fund operations into 2027.On August 7, 2024, Sera entered into a $50 million at-the-market equity offering agreement with TD Cowen. The company's PRIME study enrollment was stopped in December 2023 due to efficacy at interim analysis, with final analysis expected in fall 2024. Management continues to focus on accelerating market adoption of its PreTRM test while developing additional pipeline products.
Sera Prognostics reported Q2 2024 financial results with revenue of $24,000 and a net loss of $8.3 million, compared to $123,000 revenue and $10.5 million net loss in Q2 2023. Operating expenses decreased to $9.3 million from $11.6 million year-over-year, driven by reduced selling and marketing costs of $1.8 million and general administrative expenses of $1.2 million.The company maintained a strong financial position with $80.9 million in cash, cash equivalents and marketable securities as of June 30, 2024. Research and development expenses increased by $0.7 million to $4.4 million, primarily due to increased product development activities. The company believes its existing financial resources are sufficient to fund operations into 2027.On August 7, 2024, Sera entered into a $50 million at-the-market equity offering agreement with TD Cowen. The company's PRIME study enrollment was stopped in December 2023 due to efficacy at interim analysis, with final analysis expected in fall 2024. Management continues to focus on accelerating market adoption of its PreTRM test while developing additional pipeline products.
Sera Prognostics报告了2024年第二季度的财务结果，营业收入为24,000美元，净亏损为830万，相比于2023年第二季度的123,000美元营业收入和1050万净亏损。营业费用同比减少至930万，较1160万，主要由于销售和市场费用减少了180万，以及一般管理费用减少了120万。截至2024年6月30日，公司保持强劲的财务状况，现金、现金等价物和可交易证券达8090万。研发费用增加了70万，达到440万，主要是由于产品开发活动增加。公司认为其现有的财务资源足以支持运营到2027年。2024年8月7日，Sera与TD Cowen签订了一项5000万的市场增发协议。由于中期分析显示有效性，该公司的PRIME研究入组于2023年12月停止，最终分析预计将在2024年秋季进行。管理层继续专注于加速其PreTRm测试的市场采用，同时开发更多的潜在产品。
Sera Prognostics报告了2024年第二季度的财务结果，营业收入为24,000美元，净亏损为830万，相比于2023年第二季度的123,000美元营业收入和1050万净亏损。营业费用同比减少至930万，较1160万，主要由于销售和市场费用减少了180万，以及一般管理费用减少了120万。截至2024年6月30日，公司保持强劲的财务状况，现金、现金等价物和可交易证券达8090万。研发费用增加了70万，达到440万，主要是由于产品开发活动增加。公司认为其现有的财务资源足以支持运营到2027年。2024年8月7日，Sera与TD Cowen签订了一项5000万的市场增发协议。由于中期分析显示有效性，该公司的PRIME研究入组于2023年12月停止，最终分析预计将在2024年秋季进行。管理层继续专注于加速其PreTRm测试的市场采用，同时开发更多的潜在产品。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Baird Medical Investment Holdings
    BDMD
    -- 8.850
    NAYA Biosciences
    NAYA
    -- 0.513
    PAVmed
    PAVMZ
    -- 0.0123
    古特拉
    CUTR
    -- 0.477
    Beyond Air
    XAIR
    -- 0.418

    解锁榜首股票

    热门讨论
    特朗普2.0时代倒计时！全球股市的下一个风口？
    🎙️️讨论： 1. 加密货币政策能否利好crypto？ 2. 关税政策能否利好中概等海外资产？ 展开
    特朗普2.0机会预览：在总统上任前猜出市场赢家！